LifeVantage
LifeVantage's revenue fell 20.1% to $183 million in fiscal 2026. Its operating margin was 3.3%, down from 5.3% a year earlier. Free cash flow was $7 million, down 36.5%. It paid out $4 million in dividends and buybacks, 66% of free cash flow. The diluted share count fell 2.2%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on capital is after-tax operating income as a share of the money invested in the business: debt plus equity, minus cash. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
Income statement
From fiscal 2017 to 2026, earnings per share grew 15.4% a year and net income 13.7% a year, as buybacks cut the share count by 10%.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Cash and short-term investments | 20 | 22 | 17 | 20 | 15 |
| Debt incl. finance leases | 0 | 0 | 0 | 0 | 0 |
| Net debt (negative means net cash) | −20 | −22 | −17 | −20 | −15 |
| Net debt to EBITDA | −1.9x | −2.8x | −2.1x | −1.3x | −1.7x |
| Debt to equity | 0.0x | 0.0x | 0.0x | 0.0x | 0.0x |
| Interest coverage | 757.5x | 21.5x | 10.1x | 6,099.5x | 554.5x |
| Current ratio | 1.8x | 2.3x | 1.7x | 1.9x | 1.9x |
| Quick ratio | 1.2x | 1.4x | 1.0x | 1.1x | 1.1x |
Cash flow
Projections
Project LifeVantage's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
Insider trades
Over the 12 months between November 20, 2025 and November 19, 2026, 2 insiders bought $195,984 of LifeVantage shares on the open market, and 2 insiders sold $141,149.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Sep 15, 2026 | Darwin LewisDirector | Bought plan | 976 | $6.22 | $6,071 | Form 4 |
| Sep 14, 2026 | Kristen CunninghamChief Sales Officer | Sold | 8,901 | $6.18 | $55,008 | Form 4 |
| Sep 11, 2026 | Kristen CunninghamChief Sales Officer | Sold | 100 | $6.41 | $641 | Form 4 |
| Jun 15, 2026 | Darwin LewisDirector | Bought plan | 705 | $8.60 | $6,063 | Form 4 |
| Jun 3, 2026 | Michael A BeindorffDirector | Sold | 10,000 | $8.55 | $85,500 | Form 4 |
| Mar 16, 2026 | Darwin LewisDirector | Bought plan | 1,055 | $5.23 | $5,518 | Form 4 |
| Mar 2, 2026 | Judd DaytonDirector | Bought | 10,500 | $4.53 | $47,565 | Form 4 |
| Feb 27, 2026 | Judd DaytonDirector | Bought | 18,097 | $4.63 | $83,789 | Form 4 |
| Feb 26, 2026 | Judd DaytonDirector | Bought | 4,600 | $4.58 | $21,068 | Form 4 |
| Feb 9, 2026 | Darwin LewisDirector | Bought | 3,955 | $5.22 | $20,645 | Form 4 |
| Dec 15, 2025 | Darwin LewisDirector | Bought plan | 805 | $6.54 | $5,265 | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY24 | FY25 | FY26 |
|---|---|---|---|
| Piotroski F-score | 5 of 9 | 7 of 9 | 5 of 9 |
| Rule of 40 | −1.2% | 18.8% | −16.4% |
| Altman Z'' | −2.93 | −0.45 | −1.63 |
| Accruals ratio | −14.7% | −3.1% | −7.7% |
The nine F-score tests
| Test | FY24 | FY25 | FY26 |
|---|---|---|---|
| Net income is positive | Pass | Pass | Pass |
| Cash from operations is positive | Pass | Pass | Pass |
| Return on assets rose | Pass | Pass | Fail |
| Cash from operations exceeds net income | Pass | Pass | Pass |
| Debt fell relative to assets | Fail | Fail | Fail |
| Current ratio rose | Fail | Pass | Pass |
| Share count didn't rise | Fail | Fail | Pass |
| Gross margin rose | Fail | Pass | Fail |
| Revenue rose relative to assets | Pass | Pass | Fail |
| F-score | 5 of 9 | 7 of 9 | 5 of 9 |
Compare
Put LifeVantage side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| LifeVantage | FY26 | −20.1% | 3.3% | 3.6% | 30.8% | −1.7x | 5 | |
| Cronos Group | FY25 | 24.6% | −11.9% | 0.1% | — | — | — | Compare |
| Niagen Bioscience | FY25 | 29.9% | 12.6% | — | — | −3.8x | 6 | Compare |
| Mannatech | FY25 | −8.3% | −0.4% | −4.0% | — | −4.1x | 2 | Compare |
| The Honest Company | FY25 | −1.9% | −5.0% | 3.7% | — | — | — | Compare |
10 years of figures
| Fiscal year | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | 200 | 203 | 226 | 233 | 220 | 206 | 213 | 200 | 228 | 183 |
| Revenue growth | −3.4% | 1.9% | 11.2% | 3.1% | −5.5% | −6.3% | 3.4% | −6.2% | 14.2% | −20.1% |
| Gross profit | 166 | 168 | 188 | 195 | 182 | 168 | 170 | 159 | 184 | 142 |
| Research and development | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Operating income | 4 | 10 | 10 | 16 | 18 | 8 | 4 | 4 | 12 | 6 |
| Net income | 2 | 6 | 7 | 12 | 13 | 3 | 2 | 3 | 10 | 5 |
| Diluted EPS (US$) | 0.11 | 0.41 | 0.50 | 0.79 | 0.90 | 0.24 | 0.20 | 0.23 | 0.75 | 0.40 |
| Diluted shares (millions) | 14 | 14 | 15 | 15 | 14 | 13 | 13 | 13 | 13 | 13 |
| Cash flow | ||||||||||
| Cash from operations | 7 | 13 | 18 | 18 | 16 | 8 | 7 | 12 | 12 | 10 |
| Capital expenditure | 1 | 5 | 2 | 3 | 4 | 2 | 3 | 2 | 1 | 4 |
| Free cash flow | 6 | 9 | 15 | 16 | 13 | 6 | 4 | 10 | 11 | 7 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 7 | 2 | 2 |
| Share buybacks | 0 | 2 | 5 | 5 | 12 | 9 | 1 | 6 | 3 | 2 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4 |
| Stock-based compensation | 3 | 3 | 6 | 5 | 2 | 2 | 3 | 3 | 6 | 2 |
| Balance sheet at fiscal year end | ||||||||||
| Cash and short-term investments | 12 | 17 | 19 | 22 | 23 | 20 | 22 | 17 | 20 | 15 |
| Debt incl. finance leases | 7 | 5 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total assets | 45 | 51 | 55 | 59 | 79 | 71 | 66 | 60 | 72 | 62 |
| Total liabilities | 31 | 29 | 28 | 26 | 42 | 39 | 32 | 34 | 37 | 28 |
| Shareholders' equity | 14 | 22 | 27 | 33 | 37 | 32 | 35 | 26 | 35 | 34 |
| Margins and ratios | ||||||||||
| Gross margin | 83.2% | 82.8% | 83.2% | 83.7% | 82.7% | 81.5% | 79.7% | 79.3% | 80.4% | 77.6% |
| Operating margin | 2.2% | 5.1% | 4.3% | 6.6% | 8.0% | 3.7% | 2.0% | 2.2% | 5.3% | 3.3% |
| Net margin | 0.8% | 2.8% | 3.3% | 5.0% | 5.9% | 1.5% | 1.2% | 1.5% | 4.3% | 2.8% |
| Free cash flow margin | 2.8% | 4.2% | 6.8% | 6.7% | 5.7% | 3.1% | 1.8% | 5.0% | 4.6% | 3.6% |
| Rule of 40 (growth + FCF margin) | −0.6% | 6.1% | 18.0% | 9.8% | 0.2% | −3.2% | 5.2% | −1.2% | 18.8% | −16.4% |
| Return on capital | 21.7% | 58.7% | 76.9% | 116.3% | 106.5% | 40.4% | 22.2% | 26.4% | 83.0% | 30.8% |
| Return on equity | 12.8% | 31.6% | 30.2% | 38.2% | 36.8% | 9.1% | 7.7% | 9.7% | 32.3% | 14.9% |
| Return on assets | 3.4% | 11.9% | 14.0% | 20.2% | 18.7% | 4.2% | 3.7% | 4.7% | 14.8% | 7.6% |
| Net debt to EBITDA | −0.7x | −1.0x | −1.5x | −1.2x | −1.1x | −1.9x | −2.8x | −2.1x | −1.3x | −1.7x |